89Zr-labeled NY008 PET Imaging in Patients

Study Purpose

This is a single arm study to evaluate the safety and biodistribution of 89Zr-labeled NY008 PET Imaging in patients with multiple myeloma

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.

An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.

Searching Both is inclusive of interventional and observational studies.

Eligible Ages 18 Years and Over
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

1. Older than 18 years old, male or female; 2. Patients diagnosed with relapsing or refractory multiple myeloma; 3. LVEF≥50%; 4. ECOG score 0~2;

Exclusion Criteria:

1. Life expectancy of less than 3 months; 2. Participated in other clinical research within 1 month; 3. Recovery from major trauma (including surgery) within 28 days prior to study treatment; 4. Patients with systemic or locally severe infections, or other serious coexisting diseases; 5. Patients with abnormal immune function or who have recently used immunosuppressive or potentiating agents including various vaccines; 6. Patients with autoimmune diseases, including rheumatoid arthritis; 7. Inadequate control of arrhythmias, including atrial fibrillation; 8. Uncontrolled hypertension; 9. Patients with allergies or allergies to any component of the imaging agent or antibody; 10. Patients who cannot undergo PET/CT imaging scan; 11. Syphilis, HBV, HCV, or HIV positive subjects; 12. Male and female subjects of reproductive age cannot take effective contraceptive measures; 13. Pregnant or lactating women; 14. Patients with a history of mental illness or related conditions; 15. Other subjects considered unsuitable by researchers.

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.


Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Early Phase 1
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Affiliated Hospital of Jiangnan University
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

Principal Investigator Affiliation N/A
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Overall Status Recruiting
Countries China

The disease, disorder, syndrome, illness, or injury that is being studied.

Multiple Myeloma
Arms & Interventions


Experimental: 89Zr-NY008


Drug: - 89Zr-NY008

Patients will receive a tracer (5-10mg, IV) dose of 89Zr (2-3mCi) labelled NY008

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

International Sites

Wuxi, Jiangsu, China




Affiliated Hospital of Jiangnan University

Wuxi, Jiangsu, 214000

Site Contact

Chunjing Yu